Gottfried, Maya <br/><br/>
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.  [electronic resource] 

 -  Targeted oncology  08 2017 
 - 475-485 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1776-260X 
<br/><br/><label>Standard No.: </label>10.1007/s11523-017-0517-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adenocarcinoma of Lung<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Docetaxel<br/>Double-Blind Method<br/>Europe--epidemiology<br/>Female<br/>Humans<br/>Indoles--administration & dosage<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Survival Analysis<br/>Taxoids--administration & dosage